Pregnant women and infants are at risk should they contract mpox but there are no approved vaccines for this population.

(Reuters) -The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to ...

A clinical trial by the US National Institutes of Health (NIH) has shown that Bavarian Nordic’s mpox vaccine induced an antibody response in adolescents equivalent to that of adults. The interim ...

Emergent's vaccine is under regulatory review for mpox (formerly known as monkeypox ... a pledge of 40,000 doses from Danish drugmaker Bavarian Nordic, whose Jynneos/Imvanex/Imvamune is approved ...

(Reuters) - An initial 899,000 vaccine doses have been allocated for 9 countries across Africa that have been hit hard by the ...

The World Health Organisation has okayed Bavarian Nordic's mpox vaccine for young persons, aged between 12 and 17, as they are particularly believed to be vulnerable to outbreaks of the viral ...

COPENHAGEN, Denmark, October 29, 2024 - Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a clinical study of the MVA-BN ® mpox/smallpox vaccine in children 2 to 11 years of age.

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

The World Health Organisation said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...